

1 **Human α -actinin-3 genotype association with exercise induced muscle damage and the**
2 **repeated bout effect**

3

4 Tomas Venckunas¹, Albertas Skurvydas¹, Marius Brazaitis¹, Sigitas Kamandulis¹, Audrius
5 Snieckus¹, Colin N Moran^{2†}

6

7 ¹ Fundamental and Clinical Movement Research Center, Lithuanian Academy of Physical
8 Education, Sporto str. 6, 44221-Kaunas, Lithuania

9 ² Health and Exercise Sciences Research Group, School of Sport, University of Stirling, Stirling,
10 Scotland, FK9 4LA

11

12

13

14 [†] ***Corresponding author:***

15 Dr Colin N Moran, CBiol MSB

16 Health and Exercise Sciences Research Group

17 University of Stirling

18 Stirling, FK9 4LA

19 SCOTLAND

20

21 ***Tel:*** +44 (0)1786 466510

22 ***Fax:*** +44 (0)1786 466477

23 ***E-mail:*** colin.moran@stir.ac.uk

24

25

26 **ABSTRACT**

27 Alpha-actinin-3 (ACTN3) is an integral part of the Z-line of the sarcomere. The *ACTN3* R577X
28 (rs1815739) polymorphism determines the presence or absence of functional ACTN3 which may
29 influence the extent of exercise induced muscle damage. This study aimed to compare the impact of,
30 and recovery from, muscle-damaging eccentric exercise on subjects with or without functional alpha-
31 actinin-3. Seventeen young men (20-33 years), homozygous for the R- (n=9) or X- (n=8) alleles,
32 performed two bouts of stretch–shortening exercise (50 drop jumps) 2 weeks apart. Muscle soreness,
33 plasma creatine kinase (CK) activity, jump height, maximal voluntary isometric torque (MVC), peak
34 concentric isokinetic torque (IT), and electrically stimulated knee extension torques at 20 Hz and at
35 100 Hz were measured at baseline and a number of timepoints up to 14 days after each bout. There
36 were no significant baseline differences between the groups. However, significant
37 timepoint*genotype interactions were observed for MVC (p=0.021) and IT (p=0.011) for the
38 immediate effect of eccentric exercise in bout 1. The RR group showed greater voluntary force
39 decrements (RR v XX, MVC: -33.3% v -24.5%, IT: -35.9% v -23.2%) and slower recovery. A
40 repeated bout effect was clearly observed but there were no differences by genotype group. *ACTN3*
41 genotype modulates the response of muscle function to plyometric jumping exercise, although the
42 differences are modest. *ACTN3* genotype does not influence the clearly observed repeated bout
43 effect; however, XX homozygotes recover baseline voluntary torque values faster and thus may be
44 able to undertake more frequent training sessions.

45

46 **Keywords:** *Alpha-actinin-3*; R577X genotype; eccentric exercise; muscle damage; repeated bout
47 effect; elite athletes.

48

49

50 INTRODUCTION

51 Muscles are used to both drive movement (concentric contractions) and to act as breaks to
52 movement (eccentric contractions). Vigorous exercise of any description can result in muscle
53 damage (Clarkson et al. 1986); however, the most severe muscle damage is caused by unaccustomed
54 eccentric exercise (Newham et al. 1983), that is when contracting muscles are actively lengthening.
55 Such eccentric contractions are common during sport and are of importance because the ensuing
56 muscle damage has been associated with muscle weakness, strains and injury (Proske et al. 2004).
57 Eccentric contractions rarely occur in isolation in natural movements and are typically followed by a
58 concentric action in what is known as the stretch–shortening cycle (Byrne et al. 2004). This has also
59 been shown to elicit muscle damage, can result in severe stiffness and soreness of muscles,
60 sarcomeric disruption and a reduction in peak isometric force for several days after an exercise bout
61 (Byrne et al. 2004). Understanding the underlying contributors to this phenomenon will help to
62 understand muscle function and have implications for the design of exercise programmes.

63 Interestingly, a second bout of eccentric exercise within days or weeks of the initial muscle
64 damaging bout elicits markedly reduced symptoms of muscle damage compared with those
65 experienced after the initial bout (Clarkson et al. 1992). This phenomenon, known as the repeated
66 bout effect, is observed in both humans and animals (Mchugh 2003) although the underlying
67 mechanisms remain to be fully elucidated. Neural adaptation to the initial exercise bout may be
68 involved (Warren et al. 2000), however, the repeated bout effect has been demonstrated with
69 electrically stimulated contractions in human elbow flexors (Nosaka et al. 2002), indicating that
70 adaptations can occur independently of changes in central activation. Other hypotheses that have
71 been suggested focus primarily on subcellular structural adaptations such as: increased collagen
72 content (Lapier et al. 1995); increased serial sarcomere number (Butterfield et al. 2005; Butterfield &
73 Herzog 2006; Lynn et al. 1998); and, increased desmin content (Barash et al. 2002; Peters et al.
74 2003).

75 It has been postulated that the sarcomeric disruption caused by eccentric exercise may drive
76 the reduction in muscle functional capacity associated with eccentric exercise (Proske et al. 2004).
77 Inter-individual differences in the vulnerability of muscle tissue to exercise induced damage may be
78 in part genetically determined by variation in genes such as *alpha-actinin-3* (*ACTN3*). *ACTN3* both
79 anchors myofibrillar actin filaments to the Z-line in type II (fast) muscle fibers and is also implicated
80 in metabolic and signalling pathways through its interaction with many types of protein (Lek et al.
81 2010; Mills et al. 2001). It is of interest here primarily because of its structural role in the sarcomere
82 and a common nonsense polymorphism, R577X (rs1815739), which results in the complete absence
83 of the protein in ~16% of the global human population (North et al. 1999). These XX homozygotes
84 are, however, outwardly healthy due to functional redundancy with Alpha-actinin-2 (*ACTN2*) (North
85 et al. 1999), although genotype associations with sprinting speed (Alfred et al. 2011; Moran et al.
86 2007; Yang et al. 2003) and strength (Walsh et al. 2008) show that the redundancy is incomplete.

87 There are a limited number of conflicting reports in the literature on *ACTN3* and eccentric
88 muscle damage (Clarkson et al. 2005; Norman et al. 2009; Vincent et al. 2010); here we aimed to
89 provide a detailed assessment of muscle function before and after two bouts of muscle damaging
90 exercise, two weeks apart, to highlight associations of genotype with differences in muscle damage,
91 or function, and the repeated bout effect. We assessed jump height, a practical measure of muscle
92 function, and both maximal voluntary (MVC, maximal voluntary contraction; and IT, isokinetic peak
93 torque) and involuntary (P20, electrically stimulated knee extension torque at 20 Hz; and P100,
94 electrically stimulated knee extension torque at 100 Hz) contractions to allow differentiation between
95 maximal and submaximal stimulation of muscles. Muscle strength loss has previously been shown to
96 be a more reliable indicator of muscle damage than muscle soreness or increases in plasma protein
97 activity (Warren et al. 1999). We also assessed changes in both perceived extent of muscle damage
98 (muscle soreness) and biochemical markers (plasma CK activity).

99 If R577X polymorphism influences the response to initial and / or repeated bouts of stretch-
100 shortening exercise, its effects may be tested with the following hypotheses: firstly, due to *ACTN3*'s
101 structural role, that XX homozygotes may show an increased vulnerability to muscle damaging
102 exercise in one or both bouts; secondly, due to its involvement in intracellular signalling, that the
103 time over which indicators of such damage persist may be altered in the XX group in one or both
104 bouts; and finally, that any changes between the repeated bouts in the extent or duration of damage,
105 may be altered in the XX group. This would provide evidence that *ACTN3* genotype could account
106 for inter-individual differences in the plasticity of skeletal muscles.

107

108 MATERIALS AND METHODS

109 Ethical Approval

110 The study was approved by the Lithuanian State Ethics Committee and is consistent with the
111 principles outlined in the Declaration of Helsinki. Each subject read and signed a written informed
112 consent form prior to participation.

113 Subjects

114 Eighteen healthy young men were recruited from a larger ongoing association study based on
115 their *ACTN3* R577X genotype. This allowed selection of genotype groups of equal size (n=9). Only
116 subjects homozygous for the R-allele (*i.e.* with a complete complement of *ACTN3*), or subjects
117 homozygous for the X-allele (*i.e.* complete absence of *ACTN3*) were selected to take part. This was
118 intended to provide the largest power to detect differences between genotype groups. One subject
119 dropped out before completion of the study and was removed from all analyses. Subjects were
120 moderately physically active (< 2 h/wk) but did not take part in any regular physical exercise
121 program. They were asked to maintain their normal routine and refrain from any strenuous exercise
122 for one month prior to, and throughout the duration of, the study. Subjects with any existing medical
123 condition or taking medication that could affect natural muscle mass or function were excluded from
124 the study. Subjects were also asked to refrain from taking any pain medication during the trial.

125 Genotyping

126 DNA was extracted from blood samples using the NucleoSpin[®] Blood kit (Macherey-Nagel,
127 GmbH & Co KG, Düren, Germany) according to the manufacturer's protocol. *ACTN3* R577X
128 genotype was determined using a PCR-RFLP method described in detail in the supplementary
129 section of (Moran et al. 2007). Briefly, the primer sequences were 5'-
130 CTGGGCTGGAAGACAGGAG-3' (forward) and 5'-AGGGTGATGTAGGGATTGGTG-3'
131 (reverse). The 290 bp amplification product was digested with *DdeI* restriction enzyme (New
132 England Biolabs UK Ltd., Hitchin, Hertfordshire, UK) and separated on a 2% agarose gel. RR

133 homozygotes remained uncut; XX homozygotes had a single *DdeI* site and migrated as 192 bp and
134 98 bp bands. Subjects with RR or XX genotypes were recruited into the study.

135 **Familiarisation and Warm Ups**

136 A familiarisation session was performed one week before the initial drop jump bout (Table
137 1). Subjects were seated in the isokinetic dynamometer chair and asked to maximally activate their
138 knee extensor muscles, and then to perform five submaximal drop jumps. Their psychological
139 tolerance to electrical stimulation was assessed. All participants showed good compliance with the
140 procedure.

141 A wam-up preceded all test sessions. It comprised 6–8 min of stationary cycling with the
142 power set so that the Watts were approximately equal to the subject's body weight (kg), followed by
143 some light stretching exercises.

144 **Muscle Damaging Exercise**

145 Two drop jump bouts, separated by two weeks, were performed (Table 1). Fifty drop jumps
146 (with arms akimbo) were performed in each bout. Each drop jump comprised a jump from a 40 cm
147 elevation to a squat of 90° at the knee joints, followed immediately by a maximal counter-movement
148 vertical jump. A rest period of 20 s between jumps was chosen to minimise changes in energy
149 metabolites that could affect muscle function (Vollestad et al. 1988). This protocol has previously
150 been shown to cause measurable levels of muscle damage (Miyama & Nosaka 2007).

151 **Muscle Functional Assessments**

152 Muscle contractile properties were recorded before and immediately after (within 2–5
153 minutes) each drop jump bout then 2, 7, and 14 days into the recovery (Table 1) in the following
154 order: P20, P100, MVC, IT, and five maximal drop jumps.

155 Since maximal effort was used to jump vertically after each of the drop jumps and this was
156 performed on a contact mat (Newtest Powertimer Testing System, Oulu, Finland), the height of this
157 jump (cm) was calculated with the formula: jump height = $122.625 \times (T_f)^2$, where T_f = flight time (s)

158 (Bosco et al. 1982). To obtain a robust estimate of jump height, the average height of five
159 consecutive jumps was used for further analysis.

160 Measurements of voluntary and electrically stimulated torque were made on an isokinetic
161 dynamometer (System 3; Biodex Medical Systems, Shirley, New York) calibrated according to the
162 manufacturer's service manual with a correction for gravity performed using the Biodex Advantage
163 program (version 3.0). There was a 2 minute rest period between the electrically stimulated and
164 voluntary contractions. The coefficient of variation for involuntary and voluntary torques over
165 repeated tests was <5%.

166 MVC was measured at 120° knee angle (where 180° is full knee extension). Subjects were
167 instructed to achieve and maintain maximal efforts of knee extension for 2–3 s. Each trace was
168 visually inspected to ensure that there were no artefactual spikes at the start of the signal curve.
169 Concentric IT of the knee extensors was measured at 30°s⁻¹ (range of motion from 75° to 160°). IT at
170 30°s⁻¹ produces similar results to MVC, but allows for differences in optimal force production angle
171 (Kannus & Beynon 1993; Skurvydas et al. 2010). Briefly, subjects were asked to extend their knee
172 with maximal effort through the full range of motion, then relax and let their leg return to a neutral
173 position (~90° knee angle). Arms were crossed on the chest (hands grasping the trunk supporting
174 belts) during all tests on the dynamometer. To help ensure a maximal effort, standard vocal
175 encouragement was provided during each jump and voluntary knee extension trial by the same
176 experienced investigator. The subjects were asked to perform three attempts of each mode with a rest
177 interval of 1 min. Only the best attempt was recorded. The highest peak torque attained in each mode
178 and the knee angle at which peak torque was attained were recorded.

179 The equipment and procedure for electrically stimulated torque have been described
180 previously (Skurvydas et al. 2010). Briefly, muscle stimulation was applied using flexible surface
181 electrodes (MARP Electronic, Krakow, Poland) with one electrode (6 × 20 cm) placed transversely
182 across the width of the proximal portion of the *quadriceps femoris* next to the inguinal ligament and

183 the other electrode (6×11 cm) covering the distal portion of the muscle above the patella. A
184 constant current electrical stimulator (MG 440; Medicor, Budapest, Hungary) was used to deliver 1
185 ms square-wave pulses at 150 V. Peak torques induced by a 1 s electrical stimulation at 20 Hz (P20;
186 representing the steep section of the force-frequency relationship curve) and 100 Hz (P100; which is
187 close to maximal force) were measured with the knee at 120° with a 3 s rest interval between
188 electrical stimulations. Previous studies in humans have shown that eccentric contractions tend to
189 affect muscle force more at low frequency (*e.g.* 20 Hz) than at high frequency (*e.g.* 100 Hz)
190 stimulation and 20 and 100 Hz have previously been used in this context by others (Jones 1996). The
191 change in the P20 to P100 ratio was used as a proxy for low-frequency fatigue (Jones 1996;
192 Ratkevicius et al. 1998; Skurvydas et al. 2011).

193 **Muscle Soreness and Plasma CK Assessments**

194 Muscle soreness was reported subjectively daily throughout the study using an ordinal scale
195 of 0-10, where 0 represented “no pain” and 10 represented “intolerably intense pain” (Ratkevicius et
196 al. 1998). Participants rated the severity of soreness in their quadriceps when performing 2–3 squats
197 just before the bout 1, and then daily at the same time of day, starting 24 h after the drop jump bout.
198 Percentages for muscle soreness could not be calculated as all baseline values were zero. Therefore,
199 raw muscle soreness data were used for analyses.

200 Samples of venous blood were collected, immediately centrifuged and analysed for plasma
201 CK activity ($\mu\text{kat}\cdot\text{L}^{-1}$) using a SpotchemTM EZ SP-4430 biochemical analyser (Menarini Diagnostics,
202 Reading, UK) with soft reagent strips (ArkRay Factory Inc., Shiga, Japan). Samples for CK activity
203 were collected at baseline and 48 h, 1 week and 2 weeks after each exercise bout.

204 **Statistical Analysis**

205 Initial baseline values, for all phenotypes, were normally distributed by the Ryan-Joiner test
206 (Minitab 16.1.0). Baseline differences were assessed using unpaired t-tests. For repeated measures
207 analyses, data (except for muscle soreness) were expressed as a percentage of bout-specific baseline

208 values to account for baseline and bout variation. Prior to analyses, data were tested for normality
209 using the Ryan-Joiner test (Minitab version 16.1.0). For non-normal data, the best transformation
210 was identified using a Box-Cox analysis and data were transformed to give a better approximation of
211 the normal distribution. Means and 95% confidence intervals reported in Table 3, Figure 1 and
212 Supplementary Table 1 are back-transformed onto the original scale for ease of interpretation.
213 Further statistical analyses were carried out using SPSS 19. Data were analysed using general linear
214 model repeated measures ANOVA with appropriate Greenhouse-Geisser corrections for sphericity as
215 required. For muscle soreness, a Huynh-Feldt correction was applied for the analysis as muscle
216 soreness was ordinal data (Stiger et al. 1998). Based on the average correlation between repeated
217 measures of 0.310, we had 80% power to detect an effect size of 0.347 (G*Power v3.1.2). Where a
218 significant effect was found, *posthoc* tests were performed using LSD tests. The level of significance
219 was set at 0.05.

220

221 **RESULTS**

222 **Baseline Values**

223 There were no significant differences between genotype groups for the baseline values in any
224 of the indices measured (Table 2). Nor were there any differences in age, height, body mass or body
225 mass index (BMI) that could have confounded the data.

226 **Immediate Response to Stretch-Shortening Exercise (Bout 1)**

227 As predicted, the stretch-shortening exercise protocol produced measurable levels of muscle
228 damage immediately after the initial exercise bout (Table 3). This was evidenced by a significant
229 reduction in muscle function immediately after bout 1 whether measured by voluntary contractions
230 (MVC and IT, $p < 0.001$ for both; Figures 1A and 1B respectively) or involuntary contractions (P20
231 and P100, $p < 0.001$ for both; Figure 1D-F). Significant differences in genotype response were
232 detected for MVC and IT only (timepoint * genotype interaction terms respectively $p = 0.021$ and
233 $p = 0.011$) with greater reductions in force in the RR group (Figures 1A and 1B respectively). The
234 angle at which isokinetic peak torque was achieved was not significantly altered immediately after
235 exercise (Figure 1C). The P20 / P100 ratio was reduced by exercise similarly in both genotype
236 groups (Figure 1D-F) indicating that the exercise induced low frequency fatigue of similar
237 magnitude in both genotype groups.

238 The immediate reductions in muscle function were followed by significant increases in
239 muscle soreness ($p = 0.001$; Figure 1G) and plasma CK activity ($p < 0.001$; Figure 1H), and a
240 significant decrease in jump height ($p = 0.001$; Figure 1I). None of the responses differed by genotype
241 in repeated measures ANOVA.

242 **Timecourse of Stretch-Shortening Exercise Effects (Bout 1)**

243 Peak torque of voluntary and involuntary contractions as well as the P20 / P100 ratio
244 remained significantly lower than baseline for the duration of the post-exercise bout 1 period
245 ($p \leq 0.003$ for all timepoints; Supplementary Table 1; Figure 1D-F). Muscle soreness ($p < 0.001$), CK

246 activity ($p < 0.001$) and jump height ($p = 0.001$) remained significantly different from baseline at 2
247 days but returned to baseline values by 7 days post exercise (Supplementary Tables 1 and 2; Figures
248 G-I). The angle at which isokinetic peak torque ($p = 0.013$) was achieved was significantly altered
249 only 14 days after exercise (Figure 1C).

250 The jump height, IT and P100 of the XX group returned to baseline values quicker than the
251 RR values (Supplementary Table 1; Figures 1B, 1D-F and 1I): jump height ($p = 0.021$) and P100
252 ($p = 0.003$) of the RR group were significantly lower than baseline at day 7 when XX's had returned
253 to baseline values ($p = 0.718$ and $p = 0.136$ respectively). However, the SD of the XX group for P100
254 at day 7 was notably higher than the other days and this may have influenced this result. The IT of
255 the RR group was significantly reduced from baseline at both days 7 ($p = 0.001$) and 14 ($p = 0.001$)
256 when XX's had returned to baseline values ($p = 0.148$ and $p = 0.199$ respectively). The P20 / P100 ratio
257 was significantly lower than baseline in the XX group ($p = 0.010$) at day 14 when the RR group
258 ($p = 0.104$) had returned to baseline values.

259 For MVC, P20 and muscle soreness both genotype groups behaved similarly at all timepoints
260 after bout 1 (Supplementary Tables 1 and 2; Figures 1A and 1D-F): MVC and P20 remained
261 significantly reduced in both groups at all timepoints ($p \leq 0.013$ for all timepoints in both groups).
262 Muscle soreness was significantly higher than baseline in both genotype groups at 2 days (RR,
263 $p < 0.001$ and XX, $p = 0.001$) but returned to baseline values by 7 days.

264 **Repeated Bout Effect (Bout 2)**

265 The repeated bout effect is defined as the phenomenon whereby a second bout of muscle
266 damaging exercise results in less damage than the initial bout (Clarkson et al. 1992). As expected, this
267 effect can be seen clearly in the data: reductions in jump height, MVC, IT, P20 and P100 and
268 increases in muscle soreness and CK activity are either significantly reduced or absent after the
269 second bout of exercise (Supplementary Tables 1 and 2; Figures 1A-I) and significant interaction
270 effects for bout * timepoint can be seen for all of these phenotypes. Similar effects can be seen when

271 considering immediate effects of exercise or effects over the entire 2 week timecourse
272 (Supplementary Tables 1 and 2; Figures 1A-I). None of these effects differed significantly by
273 genotype.

274

275 **DISCUSSION**

276 There are two important findings from this study. Firstly, differences between *ACTN3*
277 genotype groups are modest and most easily detected in maximal contractions immediately after
278 exercise, with XX homozygotes appearing to retain a higher proportion of their baseline voluntary
279 torque values after stretch shortening exercise. Secondly, XX homozygotes also appear to return to
280 baseline voluntary torque values faster than RR homozygotes. However, there were no baseline
281 differences between the genotype groups or differences in their response to the repeated bout of
282 stretch shortening exercise.

283 **Muscle damage and *ACTN3* genotype**

284 The prolonged decrease in muscle force-generating capacity and increased muscle soreness
285 are consistent with classical muscle damage profiles observed after unaccustomed eccentric exercise
286 (Byrne et al. 2004). Immediately post-exercise, RR homozygotes had a greater proportional loss of
287 voluntary contraction torques (MVC and IT) and these reductions took longer to return to baseline
288 levels. These findings are counter-intuitive and in conflict with our original hypothesis, however, it
289 should be remembered that much of *ACTN3*'s function is redundant with *ACTN2* and differences
290 between the *ACTN3* genotype groups are perhaps better thought of as differences between *ACTN2*
291 and *ACTN3* function in fast muscle fibres. Nonetheless, a mechanism that would explain why
292 homozygosity for the X-allele (*i.e.* absence of *ACTN3*) confers better proportional maintenance of
293 muscle function after stretch-shortening exercise is unknown.

294 No similar genotype differences were observed in the absolute values or dynamics of the
295 indirect markers of muscle damage, such as jumping performance or muscle soreness score
296 suggesting a minor role of alpha-actinin-3 in muscle resistance to exercise induced damage, as
297 reported by others (Clarkson et al. 2005; McCauley et al. 2009). The lack of differences between
298 genotypes in involuntary muscular tension in our study could be due to stimulation only evoking
299 submaximal torques in relation to MVC: the observed tension was only about 50% and 63% of MVC

300 during electrical stimulation at 20 Hz and 100 Hz, respectively, in both groups. These are common
301 values in such types of study, but such stimulation may not be enough to stress the muscle or type II
302 fibers sufficiently to reveal the difference in intrinsic inotropic state.

303 In a cross-sectional study of the general U.S. population, female XX homozygotes have
304 previously been shown to have reduced baseline knee extensor peak torque (Walsh et al. 2008).
305 Similarly, the *actn3* knock out mouse model has reduced grip strength (MacArthur et al. 2008). It is
306 thus tempting to speculate that XX homozygotes have higher levels of underlying muscle sarcomere
307 disruption produced by normal daily living and that the extent to which they can increase muscle
308 damage and impair muscle function further may be limited. Concomitantly, a limited increase in
309 disruption would allow a return to baseline levels to occur more quickly. Studies involving much
310 larger numbers of individuals and highly detailed phenotyping would be required to address this
311 possibility.

312 Recently, differential binding of Z-disk proteins by ACTN3 and ACTN2 has been
313 demonstrated in yeast two-hybrid experiments, potentially altering the elastic properties of the
314 sarcomere (Seto et al. 2011). A desmin-knockout mouse model also provides evidence of reduced
315 vulnerability to muscle damage (Sam et al. 2000). In R-allele carriers (*i.e.* with alpha-actinin-3
316 present), the type II muscle fibers and whole skeletal muscle may generate slightly altered force
317 transduction along the myofibrils during cross-bridge cycling, provided that the integrity of the
318 sarcomeres are maintained. Thus alpha-actinin-3 itself may favor more profound Z-line streaming
319 during intense muscular exertion because of stiffer (compared to XX) thin filament binding. This
320 may explain our observation of a more pronounced decline in voluntary force production capacity of
321 RR homozygotes after a bout of drop jumps; RR homozygotes may be more efficient at the expense
322 of more depressed muscle function and prolonged recovery.

323 Vincent *et al* (2010) found a tendency for more pronounced reduction in dynamic concentric
324 peak torque at high movement speed ($200\text{--}300^\circ\text{s}^{-1}$ change in knee angle) in an XX group after a

325 single bout of muscle-damaging exercise. However, such high muscle contraction speeds generate
326 submaximal tension and force production in type II muscle fibers which may account for the
327 differences observed. They also did not find differences between genotypes in isometric or slow
328 eccentric peak torques or, in contrast to the present study, in the extent of their decrease after muscle-
329 damaging exercise. These discrepancies could be due to the different protocols used to induce
330 muscle damage and the different assessments of muscle function.

331 **The repeated bout effect**

332 A protective effect of the initial exercise bout was evidenced by quicker recovery of skeletal
333 muscle contractile function, less muscle soreness, and lower plasma CK activity after the repeated
334 bout. Sarcoskeletal alpha-actinins (2 and 3) interact with a diverse range of proteins (Lek et al. 2010)
335 and these interactions may affect the changes in type II muscle fibers after intense or damaging
336 exercise. However, the improvement did not differ between genotype groups. On the other hand, it
337 could be argued that the most important difference was in the length of the recovery period and that
338 “trainability” may be modulated by *ACTN3* genotype through the faster recovery of muscle force in
339 XX individuals after bout 1. This would allow XX homozygotes to train more frequently, benefiting
340 their long-term adaptation. However, this is a speculative suggestion and would require confirmation
341 in a larger study.

342 To understand the R577X variant, it is important to understand why the X-allele remains so
343 common in the human population (Mills et al. 2001) and why both the R- and X-alleles appear to
344 have persisted over such a long evolutionary period (Mills et al. 2001). Although some studies report
345 an X-allele association with endurance phenotypes, most do not (Alfred et al. 2011) leaving 577X
346 with no apparent advantage. In this scenario we would expect removal of the 577X allele from the
347 population and fixation of 577R, which clearly has not occurred. From the available data, it may be
348 that the R-allele confers an advantage in concentric exercise, improving strength performance, whilst

349 the X-allele protects against relative loss of function in the days following a bout of exercise
350 involving eccentric contractions.

351 In conclusion, homozygosity for the ACTN3 577X allele may reduce the relative functional
352 loss and provide a faster recovery of functionality to normal levels in response to unaccustomed
353 plyometric exercise. However, the difference between genotypes is modest and the mechanism by
354 which the difference is mediated remains elusive. Future studies in this area must involve
355 significantly larger groups of subjects to ensure sufficient power to investigate what appear to be
356 subtle differences.

357

358

359 **Acknowledgements**

360 The authors wish to thank all volunteers for their participation in this study. This work was
361 funded by a grant from the Lithuanian Academy of Physical Education.

362

363 **Conflicts of Interest**

364 The authors have no conflicts of interest to declare.

365

References

- 366
367
- 368 Alfred, T., Ben-Shlomo, Y., Cooper, R., Hardy, R., Cooper, C., Deary, I.J., Gunnell, D., Harris, S.E.,
369 Kumari, M., Martin, R.M., Moran, C.N., Pitsiladis, Y.P., Ring, S.M., Sayer, A.A., Smith, G.D.,
370 Starr, J.M., Kuh, D., and Day, I.N. 2011. ACTN3 genotype, athletic status and lifecourse physical
371 capability: meta-analysis of the published literature and findings from nine studies. *Hum. Mutat.*
372 32: 1008-1018.
- 373 Barash, I.A., Peters, D., Friden, J., Lutz, G.J., and Lieber, R.L. 2002. Desmin cytoskeletal modifications
374 after a bout of eccentric exercise in the rat. *American Journal of Physiology-Regulatory*
375 *Integrative and Comparative Physiology* 283: R958-R963.
- 376 Bosco, C., Viitasalo, J.T., Komi, P.V., and Luhtanen, P. 1982. Combined Effect of Elastic Energy and
377 Myoelectrical Potentiation During Stretch-Shortening Cycle Exercise. *Acta Physiologica*
378 *Scandinavica* 114: 557-565.
- 379 Butterfield, T.A. and Herzog, W. 2006. The magnitude of muscle strain does not influence serial
380 sarcomere number adaptations following eccentric exercise. *Pflugers Arch.* 451: 688-700.
- 381 Butterfield, T.A., Leonard, T.R., and Herzog, W. 2005. Differential serial sarcomere number
382 adaptations in knee extensor muscles of rats is contraction type dependent. *J. Appl. Physiol* 99:
383 1352-1358.
- 384 Byrne, C., Twist, C., and Eston, R. 2004. Neuromuscular function after exercise-induced muscle
385 damage - Theoretical and applied implications. *Sports Medicine* 34: 49-69.

- 386 Clarkson,P.M., Byrnes,W.C., McCormick,K.M., Turcotte,L.P., and White,J.S. 1986. Muscle
387 soreness and serum creatine kinase activity following isometric, eccentric, and concentric
388 exercise. *Int. J. Sports Med.* 7: 152-155.
- 389 Clarkson,P.M., Hoffman,E.P., Zambraski,E., Gordish-Dressman,H., Kearns,A., Hubal,M.,
390 Harmon,B., and Devaney,J.M. 2005. ACTN3 and MLCK genotype associations with exertional
391 muscle damage. *Journal of Applied Physiology* 99: 564-569.
- 392 Clarkson,P.M., Nosaka,K., and Braun,B. 1992. Muscle Function After Exercise-Induced Muscle
393 Damage and Rapid Adaptation. *Medicine and Science in Sports and Exercise* 24: 512-520.
- 394 Jones,D.A. 1996. High- and low-frequency fatigue revisited. *Acta Physiologica Scandinavica* 156:
395 265-270.
- 396 Kannus,P. and Beynnon,B. 1993. Peak torque occurrence in the range of motion during isokinetic
397 extension and flexion of the knee. *Int. J. Sports Med.* 14: 422-426.
- 398 Lapier,T.K., Burton,H.W., Almon,R., and Cerny,F. 1995. Alterations in Intramuscular Connective-
399 Tissue After Limb Casting Affect Contraction-Induced Muscle Injury. *Journal of Applied*
400 *Physiology* 78: 1065-1069.
- 401 Lek,M., Quinlan,K.G.R., and North,K.N. 2010. The evolution of skeletal muscle performance: gene
402 duplication and divergence of human sarcomeric alpha-actinins. *Bioessays* 32: 17-25.
- 403 Lynn,R., Talbot,J.A., and Morgan,D.L. 1998. Differences in rat skeletal muscles after incline and
404 decline running. *Journal of Applied Physiology* 85: 98-104.

- 405 MacArthur,D.G., Seto,J.T., Chan,S., Quinlan,K.G.R., Raftery,J.M., Turner,N., Nicholson,M.D.,
406 Kee,A.J., Hardeman,E.C., Gunning,P.W., Cooney,G.J., Head,S.I., Yang,N., and North,K.N. 2008.
407 An Actn3 knockout mouse provides mechanistic insights into the association between alpha-
408 actinin-3 deficiency and human athletic performance. *Human Molecular Genetics* 17: 1076-1086.
- 409 McCauley,T., Mastana,S.S., Hossack,J., MacDonald,M., and Folland,J.P. 2009. Human angiotensin-
410 converting enzyme I/D and alpha-actinin 3 R577X genotypes and muscle functional and
411 contractile properties. *Experimental Physiology* 94: 81-89.
- 412 Mchugh,M.P. 2003. Recent advances in the understanding of the repeated bout effect: the protective
413 effect against muscle damage from a single bout of eccentric exercise. *Scandinavian Journal of*
414 *Medicine & Science in Sports* 13: 88-97.
- 415 Mills,M.A., Yang,N., Weinberger,R.P., Vander Woude,D.L., Beggs,A.H., Easteal,S., and North,K.N.
416 2001. Differential expression of the actin-binding proteins, alpha-actinin-2 and-3, in different
417 species: implications for the evolution of functional redundancy. *Human Molecular Genetics* 10:
418 1335-1346.
- 419 Miyama,M. and Nosaka,K. 2007. Protection against muscle damage following fifty drop jumps
420 conferred by ten drop jumps. *Journal of Strength and Conditioning Research* 21: 1087-1092.
- 421 Moran,C.N., Yang,N., Bailey,M.E.S., Tsiokanos,A., Jamurtas,A., MacArthur,D.G., North,K.,
422 Pitsiladis,Y.P., and Wilson,R.H. 2007. Association analysis of the ACTN3 R577X polymorphism
423 and complex quantitative body composition and performance phenotypes in adolescent Greeks.
424 *European Journal of Human Genetics* 15: 88-93.

- 425 Newham,D.J., Mcphail,G., Mills,K.R., and Edwards,R.H.T. 1983. Ultrastructural-Changes After
426 Concentric and Eccentric Contractions of Human-Muscle. *Journal of the Neurological Sciences*
427 61: 109-122.
- 428 Norman,B., Esbjornsson,M., Rundqvist,H., Osterlund,T., von Walden,F., and Tesch,P.A. 2009.
429 Strength, power, fiber types, and mRNA expression in trained men and women with different
430 ACTN3 R577X genotypes. *Journal of Applied Physiology* 106: 959-965.
- 431 North,K.N., Yang,N., Wattanasirichaigoon,D., Mills,M., Easteal,S., and Beggs,A.H. 1999. A
432 common nonsense mutation results in alpha-actinin-3 deficiency in the general population. *Nature*
433 *Genetics* 21: 353-354.
- 434 Nosaka,K., Newton,M., and Sacc,P. 2002. Delayed-onset muscle soreness does not reflect the
435 magnitude of eccentric exercise-induced muscle damage. *Scandinavian Journal of Medicine &*
436 *Science in Sports* 12: 337-346.
- 437 Peters,D., Barash,I.A., Burdi,M., Yuan,P.S., Mathew,L., Friden,J., and Lieber,R.L. 2003.
438 Asynchronous functional, cellular and transcriptional changes after a bout of eccentric exercise in
439 the rat. *Journal of Physiology-London* 553: 947-957.
- 440 Proske,U., Morgan,D.L., Brockett,C.L., and Percival,P. 2004. Identifying athletes at risk of
441 hamstring strains and how to protect them. *Clin. Exp. Pharmacol. Physiol* 31: 546-550.
- 442 Ratkevicius,A., Skurvydas,A., Povilonis,E., Quistorff,B., and Lexell,J. 1998. Effects of contraction
443 duration on low-frequency fatigue in voluntary and electrically induced exercise of quadriceps
444 muscle in humans. *European Journal of Applied Physiology* 77: 462-468.

- 445 Sam,M., Shah,S., Friden,J., Milner,D.J., Capetanaki,Y., and Lieber,R.L. 2000. Desmin knockout
446 muscles generate lower stress and are less vulnerable to injury compared with wild-type muscles.
447 *American Journal of Physiology-Cell Physiology* 279: C1116-C1122.
- 448 Seto,J.T., Lek,M., Quinlan,K.G., Houweling,P.J., Zheng,X.F., Garton,F., MacArthur,D.G.,
449 Raftery,J.M., Garvey,S.M., Hauser,M.A., Yang,N., Head,S.I., and North,K.N. 2011. Deficiency of
450 {alpha}-actinin-3 is associated with increased susceptibility to contraction-induced damage and
451 skeletal muscle remodeling. *Hum. Mol. Genet.* 20: 2914-2927.
- 452 Skurvydas,A., Brazaitis,M., Kamandulis,S., and Sipaviciene,S. 2010. Peripheral and central fatigue
453 after muscle-damaging exercise is muscle length dependent and inversely related. *Journal of*
454 *Electromyography and Kinesiology* 20: 655-660.
- 455 Skurvydas,A., Brazaitis,M., Venckunas,T., and Kamandulis,S. 2011. Predictive value of strength loss
456 as an indicator of muscle damage across multiple drop jumps. *Applied Physiology Nutrition and*
457 *Metabolism-Physiologie Appliquee Nutrition et Metabolisme* 36: 353-360.
- 458 Stiger,T.R., Kosinski,A.S., Barnhart,H.X., and Kleinbaum,D.G. 1998. Anova for repeated ordinal
459 data with small sample size? A comparison of ANOVA, MANOVA, WLS and GEE methods by
460 simulation. *Communications in Statistics-Simulation and Computation* 27: 357-375.
- 461 Vincent,B., Windelinckx,A., Nielens,H., Ramaekers,M., Van Leemputte,M., Hespel,P., and
462 Thomis,M.A. 2010. Protective role of alpha-actinin-3 in the response to an acute eccentric
463 exercise bout. *Journal of Applied Physiology* 109: 564-573.

- 464 Vollestad,N.K., Sejersted,O.M., Bahr,R., Woods,J.J., and Biglandritchie,B. 1988. Motor drive and
465 metabolic responses during repeated submaximal contractions in humans. *Journal of Applied*
466 *Physiology* 64: 1421-1427.
- 467 Walsh,S., Liu,D.M., Metter,E.J., Ferrucci,L., and Roth,S.M. 2008. ACTN3 genotype is associated
468 with muscle phenotypes in women across the adult age span. *Journal of Applied Physiology* 105:
469 1486-1491.
- 470 Warren,G.L., Hermann,K.M., Ingalls,C.P., Masselli,M.R., and Armstrong,R.B. 2000. Decreased
471 EMG median frequency during a second bout of eccentric contractions. *Medicine and Science in*
472 *Sports and Exercise* 32: 820-829.
- 473 Warren,G.L., Lowe,D.A., and Armstrong,R.B. 1999. Measurement tools used in the study of
474 eccentric contraction-induced injury. *Sports Medicine* 27: 43-59.
- 475 Yang,N., MacArthur,D.G., Gulbin,J.P., Hahn,A.G., Beggs,A.H., Easteal,S., and North,K. 2003.
476 ACTN3 genotype is associated with human elite athletic performance. *American Journal of*
477 *Human Genetics* 73: 627-631.
- 478
- 479

TABLES

Table 1. Study testing protocol

	Day -7	Day 0			Day 2	Day 7	Day 14			Day 16	Day 21	Day 28
		baseline	exercise	post-ex			pre-ex	exercise	post-ex			
Familiarisation session	•											
Stretch shortening exercise bout			•					•				
Muscle soreness evaluation		<i>Measured daily throughout the study</i>										
Plasma sample for CK activity		•			•	•	•			•	•	•
Muscle functional assessments ¹		•		•	•	•	•		•	•	•	•

¹ Jump height, maximal voluntary isometric torque, peak concentric isokinetic torque and electrically stimulated knee extension torques at 20 Hz and at 100 Hz.

Table 2. Baseline values of anthropometric measurements, muscle damage and muscle function indices.

	<i>RR</i> (<i>n</i> =9)	<i>XX</i> (<i>n</i> =8)	p-value (unpaired t-test)
Age (years)	25.1 ± 1.5	25.8 ± 1.2	0.749
Height (m)	180.9 ± 1.9	181.7 ± 2.5	0.793
Body Mass (kg)	77.4 ± 2.4	79.8 ± 4.7	0.649
BMI (kg·m ⁻²)	23.7 ± 0.9	24.1 ± 1.0	0.797
Muscle soreness	0 ± 0	0 ± 0	NA
CK activity (μkat·L ⁻¹)	2.9 ± 0.7	3.1 ± 0.8	0.897
Jump height (cm)	40.3 ± 2.5	37.8 ± 2.4	0.486
MVC (Nm)	292.1 ± 23.9	284.2 ± 19.2	0.802
IT (Nm)	252.0 ± 17.5	238.3 ± 11.4	0.532
ITA (degrees)	126.0 ± 2.6	121.9 ± 3.5	0.348
P20 (Nm)	146.5 ± 10.0	136.5 ± 10.5	0.500
P100 (Nm)	188.5 ± 15.2	171.3 ± 14.3	0.425
P20 / P100	0.79 ± 0.029	0.81 ± 0.033	0.658

Values given are mean ± standard error of the mean. BMI, body mass index; CK, plasma creatine kinase; MVC, maximal voluntary contraction torque; IT, peak isokinetic torque; ITA, angle at which IT was achieved; P20, P100, torques evoked by 20 Hz and 100 Hz electrical stimulation.

Table 3. Immediate bout 1 exercise induced changes in muscle damage and muscle function indices for both *ACTN3* genotype groups.

	<i>Combined Group</i> (<i>n</i> =17)	<i>p-value</i> ^a	<i>RR Group</i> (<i>n</i> =9)	<i>p-value</i> ^b	<i>XX Group</i> (<i>n</i> =8)	<i>p-value</i> ^c	<i>p-value</i> ^d
Muscle soreness	4.5 (3.4 to 5.6)	< 0.001	4.5 (2.8 to 6.3)	< 0.001	4.5 (3.1 to 5.8)	< 0.001	0.938
CK activity [†]	72.5 (35.1 to 127.9)	< 0.001	72.1 (26.4 to 147.7)	0.008	73.1 (15.3 to 188.4)	0.040	0.983
Jump height	-6.0 (-8.8 to -3.3)	0.001	-6.6 (-10.6 to -2.6)	0.012	-5.5 (-9.6 to -1.4)	0.035	0.712
MVC	-29.1 (-33.0 to -25.2)	< 0.001	-33.3 (-37.6 to -29.0)	< 0.001	-24.5 (-29.7 to -19.2)	< 0.001	0.021
IT	-29.7 (-35.1 to -24.6)	< 0.001	-35.9 (-40.4 to -31.8)	< 0.001	-23.2 (-31.0 to -16.1)	0.001	0.011
ITA	-1.7 (-5.8 to 2.1)	0.398	-1.2 (-5.9 to 3.0)	0.595	-2.2 (-9.8 to 4.3)	0.544	0.813
P20	-65.7 (-69.8 to -61.6)	< 0.001	-67.4 (-71.5 to -63.3)	< 0.001	-63.8 (-71.4 to -56.2)	< 0.001	0.408
P100	-34.4 (-41.2 to -27.6)	< 0.001	-38.0 (-47.3 to -28.6)	< 0.001	-30.5 (-40.3 to -20.6)	0.001	0.298
P20 / P100	-46.5 (-50.9 to -42.4)	< 0.001	-45.4 (-52.1 to -39.5)	< 0.001	-47.7 (-53.8 to -42.3)	< 0.001	0.608

All values are mean change (95% confidence interval) from baseline to immediately post-exercise change as a percentage of baseline value except, CK activity and jump height which are baseline to 48 hour change and muscle soreness which is absolute change from baseline to 24 hours. CK, plasma creatine kinase; MVC, maximal voluntary contraction torque; IT, peak isokinetic torque; ITA, angle at which IT was achieved; P20, P100, torques evoked by 20 Hz and 100 Hz electrical stimulation. [†] N-values for RR and XX are 8 and 6 respectively for CK only. Post-hoc tests are t-tests, other p-values are from repeated measures ANOVAs: ^a exercise term, ^b Post-hoc exercise term for RR group only, ^c Post-hoc exercise term for XX group only, ^d Interaction between genotype group and exercise term.

FIGURES AND LEGENDS

Fig. 1 (a) Percentage change in MVC, (b) percentage change in IT, (c) percentage change in ITA, (d) percentage change in P20, (e) percentage change in P100, (f) percentage change in P20 / P100, (g) absolute change in muscle soreness, (h) percentage change in plasma CK activity, (i) percentage change in jump height, post-exercise bout 1 (solid fill; RR ■, and XX ■) and bout 2 (diagonal pattern fill; RR ▨, XX ▨) in both ACTN3 genotype groups. Error bars are SEM. Post-hoc tests are t-tests, other p-values are from repeated measures ANOVAs: * p<0.05 post hoc compared with pre-exercise (paired t-test); ∞ p<0.05 post hoc compared with equivalent timepoint and group in bout 1 (paired t-test); # p<0.05 post hoc compared with RR at same timepoint and bout (unpaired t-test).

